Alf Gunnar Martin Nicklasson is a Swedish businessperson who has been the head of 13 different companies and presently is Chairman at Zealand Pharma A, Chairman of Nykode Therapeutics ASA, Chairman at Sanivo Pharma AS and Non-Executive Chairman of Kymab Ltd.

He is also on the board of Basilea Pharmaceutica AG (former Chairman), BioCrine AB, Stockholm Chamber of Commerce and Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt and Associate Professor at the University of Uppsala, Member of Royal Swedish Academy of Engineering Sciences, Member of The Royal Bachelors' Club, Member of Swedish Academy For Pharmaceutical Sciences and Senior Partner at Nicklasson Life Science AB.

He previously held the position of Chairman of Orexo AB, Chairman for Farma Investment AS, Chief Executive Officer of Astra Hässle AB, President & Chief Executive Officer of Swedish Orphan Biovitrum AB President & Chief Executive Officer of Biovitrum AB and Chief Executive Officer at Swedish Orphan International Holding AB (both are subsidiaries of Swedish Orphan Biovitrum AB), Chief Executive Officer of Astra Pain Control AB and EVP-Product Strategy & Business Development at AstraZeneca Plc and Chief Executive Officer for AstraZeneca AB (a subsidiary of AstraZeneca Plc).

He received a graduate degree and a doctorate from the University of Uppsala.